• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

OncoVista Innovative Therapies, Inc. Announces Initiation of Research Coverage By Status Equity Research

Posted on: Tuesday, 12 August 2008, 12:02 CDT

OncoVista Innovative Therapies Inc. (OTC BB: OVIT), a biopharmaceutical company engaged in the development and commercialization of targeted cancer therapies and diagnostics, announced today that Status Equity Research has initiated research coverage on the Company with a rating of Accumulate and a 36 month price target of $16 per share.

The research report can be accessed at www.statusequity.com on the "Status Research" tab.

About Status Equity Research:

Status Equity Research is a monthly publication committed to providing coverage on unique emerging growth companies that can become sector leaders in the U.S. equity markets. Status Equity Research also provides market commentary, perspectives on geopolitical affairs and global economic issues. Status Equity Research's core desired goal is to provide well rounded access to emerging growth companies that currently have limited visibility, yet possess significant prospects for growth.

About OncoVista, Inc.

OncoVista is a biopharmaceutical company engaged in the development and commercialization of targeted cancer therapies both through the acquisition of rights to technologies and drugs from others and through the development of proprietary products. OncoVista intends to identify, develop and rapidly commercialize innovative therapies for safer and more efficacious treatment of cancer. OncoVista believes that the development of targeted approaches to the administration of anticancer agents should lead to improved outcomes and/or reduced toxicity. In targeting compounds for acquisition, OncoVista focuses on candidates that have been previously tested in human clinical trials or animal models, as well as technologies that may improve the delivery or targeting of previously tested, and in some cases marketed, anticancer agents. OncoVista's senior management team and its panel of internationally-recognized clinical advisors have made significant contributions to the development of leading drugs currently used in cancer treatment. Its management, in conjunction with its advisors, intend to evaluate in-licensing candidates based on several criteria, including development and registration strategies to be employed, commercialization opportunities and competitive technologies being developed elsewhere. OncoVista's primary therapeutic strategy is based on targeting the patient's tumor(s) with treatments that will deliver drugs selectively based upon specific biochemical characteristics of the cancer cells comprising the tumor. Through a combination of licensing agreements as well as mergers and acquisitions, OncoVista has acquired the rights to several technologies with the potential to more effectively treat cancers and significantly improve quality-of-life for patients.

Forward-Looking Statements: A number of statements contained in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the applicable statements. These risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the applicable statements.

Source: Business Wire

More News in this Category